Categories
wellbeing news

New stimulus for deep transcranial magnetic stimulation BrainsWay celebrates its German premiere at the Congress of the German Society for Psychiatry, Psychotherapy and Psychosomatics 20

JERUSALEM, November 25, 2019 (GLOBE NEWSWIRE) – Brainsway Ltd. (NASDAQ: BWAY, TASE: BWAY), the world leader in advanced non-invasive treatment for brain disorders, announced today for the first time in Germany the launch of a new modern platform of deep transcranial magnetic stimulation (dTMS) in Germany at the Congress of the German Society for Psychiatry, Psychotherapy and psychosomatics (DGPPN) 2019 to be held from 27 to 30 November 2019 in Berlin. The platform includes a new proprietary stimulator and is designed to treat a variety of neuropsychiatric conditions, including major depressive disorder (MDD) and obsessive compulsive disorder (OCD).

BrainsWay will hold individual, hands-on demonstrations by interested physicians at booth # 12 to share their up-close personal experience with a new dTMS stimulator and gain a better understanding of how it works and how it works.

The new platform combines powerful dTMS treatment with first-class, innovative design. The new BrainsWay stimulator features a user interface with an integrated patient management system and tools to accurately and quickly determine the threshold and position of the motor coil.

“BrainsWay dTMS technology is an important option for many patients with neuropsychiatric indications resistant to treatment. Peter Tonn, Hamburg-Alton Neuropsychiatric Center. "The annual DGPPN Congress in Berlin is a great opportunity to showcase a new BrainsWay stimulator and to inform well-known European healthcare professionals about the features and availability of BrainsWay's innovative technology."

Deep TMS is currently available in the US for MDD and OCD and is FDA approved. In Europe, the device is CE certified for various neuropsychiatric disorders. The technology has been tested in more than 60 clinical trials worldwide and provides an alternative treatment option to patients who have not responded well to medication or a combination of psychotherapy and medication.

For more information, see:https://www.brainsway.com/

About DGPPN
DGPPN is the largest scientific medical association focusing on mental health in Germany. It brings together the expertise of 9,400 psychiatric, psychotherapy and psychosomatic physicians and scientists working in university and non-university hospitals, medical practices and research. The association is committed to providing optimal care for patients with mental illness. Develops scientific guidelines, promotes education, training and further education and is involved in mental illness research to improve diagnosis and treatment. The focus is on a holistic portrayal of a person and his or her individual mental, physical and social characteristics. DGPPN actively participates in the participation of people with mental illness in society and their stigmatization.

About BrainsWay
BrainsWay is a commercial medical device company focused on the development and sale of non-invasive neuromodulation products that use proprietary deep transcranial magnetic stimulation (Deep TMS) technologies to treat major depressive disorders (MDD) and obsessive-compulsive disorders (ADR). , OCD), for BrainsWay in 2013 (for MDD) and in August 2018 (for OCD), U.S. market approval. Food and Drug Administration (FDA). The company's products are CE certified for various other designations in Europe. BrainsWay is currently conducting clinical trials of Deep TMS for other psychiatric, neurological and addictive disorders, including smoking cessation and post-traumatic stress disorder, and plans to study opioid dependence, multiple sclerosis (MS) fatigue and rehabilitation after stroke.

Statements for the future
This statement contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. Such statements may use the words "intend", "may", "will", "plan", "expect", "anticipate", "project ". "," predict "," evaluate "," target "," believe "," hope "," possible "or similar words. These forward-looking statements and their effects are based solely on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in forward-looking statements, in addition, the historical results or conclusions of scientific research and clinical studies do not guarantee that future results will suggest similar conclusions or will be mentioned here. In addition, certain information in this news release is based on information from a study from outside the United States that has not been reviewed by the US Food and Drug Administration and which may be subject to various statistical analyzes that affect the information contained here could may differ materially from those described in the future statements, including but not limited to the following factors: Insufficient financial resources to cover future capital requirements; Changes in technology and market requirements; Delays or obstacles in conducting and / or successfully completing planned studies and clinical trials; Failure to obtain regulatory approvals during the expected timeframe of the entity or at all; Inability to retain or attract key personnel whose knowledge is essential to the development of Deep TMS products and processes; unforeseen difficulties with Deep TMS products and processes and / or inability to develop necessary improvements; unexpected costs associated with Deep TMS products; Failure to achieve and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the possibility of product liability; Changes in legislation and applicable rules and regulations; adverse market perception and adoption of deep TMS technology; insufficient or late third party reimbursement, including insurance companies and Medicare; Inability to market Deep TMS internationally through the Company or through third party distributors; competitors; product development; The inability to rapidly develop and introduce new technologies, products and applications that could cause the Company's actual results or performance to differ materially from those anticipated in such forecasts.

All forward-looking statements in this release are for the date of this news only. The Company is under no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable securities law. More detailed information on the risks and uncertainties affecting the Company can be found under the heading "Risk Factors" in the "Risk Factors" section. Securities and Exchange Commission.

Media Contact:
Erich Sandoval
Lazar Partners
Phone: +1 917-497-2867
esandoval@lazarpartners.com

New stimulus for deep transcranial magnetic stimulation BrainsWay celebrates its German premiere at the Congress of the German Society for Psychiatry, Psychotherapy and Psychosomatics 20 3